<HashMap><database>biostudies-literature</database><scores/><additional><submitter>LeBlanc KR</submitter><funding>BLRD VA</funding><funding>NIA NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIH HHS</funding><pagination>ugaf032</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12469191</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(3)</volume><pubmed_abstract>Alzheimer's disease (AD) and other tauopathies are neurodegenerative disorders with devastating consequences for cognition and memory. Pathogenic accumulation of tau can be modeled in &lt;i>Caenorhabditis elegans&lt;/i>, which recapitulate human neurodegeneration including aging-dependent accumulation of phosphorylated tau, tau aggregation, neuronal dysfunction, and neuron degeneration. Using forward genetic screens to identify genes modulating tau pathology, we identified a single point mutation in &lt;i>dib-1&lt;/i> that ameliorates tau-driven behavioral defects, prevents neurodegeneration, and decreases tau protein levels. The &lt;i>dib-1&lt;/i> gene encodes a small, highly conserved protein, known as TXNL4A in humans, and participates in mRNA splicing via the U4/U6.U5 tri-snRNP. Notably, heterozygous lo</pubmed_abstract><journal>NAR molecular medicine</journal><pubmed_title>Tri-snRNP activity modulates tauopathy phenotypes.</pubmed_title><pmcid>PMC12469191</pmcid><funding_grant_id>F99 AG088436</funding_grant_id><funding_grant_id>U19 AG066567</funding_grant_id><funding_grant_id>I01 BX005762</funding_grant_id><funding_grant_id>R01 AG084680</funding_grant_id><funding_grant_id>R01 AG066729</funding_grant_id><funding_grant_id>T32 AG052354</funding_grant_id><funding_grant_id>P40 OD010440</funding_grant_id><funding_grant_id>R01 AG084552</funding_grant_id><funding_grant_id>R01 NS064131</funding_grant_id><funding_grant_id>IK6 BX006467</funding_grant_id><funding_grant_id>P30 AG066509</funding_grant_id><pubmed_authors>Liachko NF</pubmed_authors><pubmed_authors>Saxton AD</pubmed_authors><pubmed_authors>Wheeler JM</pubmed_authors><pubmed_authors>Latimer CS</pubmed_authors><pubmed_authors>LeBlanc KR</pubmed_authors><pubmed_authors>Eck RJ</pubmed_authors><pubmed_authors>Kow RL</pubmed_authors><pubmed_authors>Kraemer BC</pubmed_authors><pubmed_authors>McMillan PJ</pubmed_authors><pubmed_authors>Keene CD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tri-snRNP activity modulates tauopathy phenotypes.</name><description>Alzheimer's disease (AD) and other tauopathies are neurodegenerative disorders with devastating consequences for cognition and memory. Pathogenic accumulation of tau can be modeled in &lt;i>Caenorhabditis elegans&lt;/i>, which recapitulate human neurodegeneration including aging-dependent accumulation of phosphorylated tau, tau aggregation, neuronal dysfunction, and neuron degeneration. Using forward genetic screens to identify genes modulating tau pathology, we identified a single point mutation in &lt;i>dib-1&lt;/i> that ameliorates tau-driven behavioral defects, prevents neurodegeneration, and decreases tau protein levels. The &lt;i>dib-1&lt;/i> gene encodes a small, highly conserved protein, known as TXNL4A in humans, and participates in mRNA splicing via the U4/U6.U5 tri-snRNP. Notably, heterozygous lo</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-05-31T03:09:27.308Z</modification><creation>2026-05-31T03:07:19.805Z</creation></dates><accession>S-EPMC12469191</accession><cross_references><pubmed>41256288</pubmed><doi>10.1093/narmme/ugaf032</doi></cross_references></HashMap>